Fibroblast Activation Protein (FAP or Seprase) Inhibitors -Pipeline Insights, 2016

Description:
SUMMARY
The report, “Fibroblast Activation Protein (FAP or Seprase) Inhibitors-Pipeline Insights, 2016” provides in-depth insights on the pipeline drugs and their development activities around the Fibroblast Activation Protein (FAP or Seprase) Inhibitors. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Fibroblast Activation Protein (FAP or Seprase) Inhibitors. The report also assesses the Fibroblast Activation Protein (FAP or Seprase) Inhibitors therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Fibroblast Activation Protein (FAP or Seprase) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Fibroblast Activation Protein (FAP or Seprase) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete MOA intelligence and complete understanding over therapeutics development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Fibroblast Activation Protein (FAP or Seprase) Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence-based Decisions

Contents:
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Overview
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Disease Associated
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Pipeline Therapeutics
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Therapeutics under Development by Companies
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Filed and Phase III Products
- Comparative Analysis
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Phase II Products
- Comparative Analysis
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors – Therapeutics Assessment
  - Assessment by Monotherapy Products
  - Assessment by Combination Products
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors – Discontinued Products
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors – Dormant Products
- Companies Involved in Therapeutics Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables
- Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors by Therapy Area, 2016
- Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Monotherapy Products
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Combination Products
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Route of Administration
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Route of Administration
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Molecule Type
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assesment by Stage and Molecule Type
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Therapeutics – Discontinued Products
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Therapeutics – Dormant Products
- Products under Development by Companies, 2016

List of Figures
- Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors by Therapy Area, 2016
- Number of Products under Development for Fibroblast Activation Protein (FAP or Seprase) Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Monotherapy Products
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Combination Products
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Route of Administration
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Route of Administration
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Molecule Type
- Fibroblast Activation Protein (FAP or Seprase) Inhibitors Assessment by Stage and Molecule Type
Ordering:  


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Fibroblast Activation Protein (FAP or Seprase) Inhibitors -Pipeline Insights, 2016
Web Address: http://www.researchandmarkets.com/reports/3534413/
Office Code: SCD2FP83

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 1250</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof] [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

    Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp